MARC details
000 -LEADER |
fixed length control field |
03399nam a22003737a 4500 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
201231s20202020 xxu||||| |||| 00| 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
International Standard Serial Number |
2198-6576 |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1007/s40744-020-00243-2 [doi] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1007/s40744-020-00243-2 [pii] |
024 ## - OTHER STANDARD IDENTIFIER |
Standard number or code |
PMC7695800 [pmc] |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
Ovid MEDLINE(R) |
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
PMID |
33206344 |
245 ## - TITLE STATEMENT |
Title |
Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. |
251 ## - Source |
Source |
Rheumatology & Therapy. 7(4):949-965, 2020 Dec. |
252 ## - Abbreviated Source |
Abbreviated source |
Rheumatol. ther.. 7(4):949-965, 2020 Dec. |
253 ## - Journal Name |
Journal name |
Rheumatology and therapy |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Year |
2020 |
260 ## - PUBLICATION, DISTRIBUTION, ETC. |
Manufacturer |
FY2021 |
265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
Publication status |
ppublish |
266 ## - Date added to catalog |
Date added to catalog |
2020-12-31 |
520 ## - SUMMARY, ETC. |
Abstract |
CONCLUSIONS: Belimumab improves clinical manifestations of SLE and is associated with GCS dose reductions in a real-world clinical setting, supporting the real-world effectiveness of belimumab for SLE. |
520 ## - SUMMARY, ETC. |
Abstract |
INTRODUCTION: The real-world effectiveness of belimumab for systemic lupus erythematosus (SLE) in six countries was evaluated in the OBSErve program. The aim of this post hoc analysis (GSK study 206351) was to pool individual patient OBSErve data to further evaluate the effectiveness of belimumab in a large sample of patients with SLE. |
520 ## - SUMMARY, ETC. |
Abstract |
METHODS: OBSErve (Argentina, Canada, Germany, Spain, Switzerland, and the USA) enrolled adults >= 18 years of age with SLE, who were prescribed belimumab as part of standard therapy (index: date of belimumab initiation). Endpoints (month 6 vs. index) included physician-assessed overall clinical response to belimumab in the overall population (primary) and high disease activity subgroups (secondary; patients with a SLEDAI-2K/SELENA-SLEDAI score >= 10 or patients with high anti-dsDNA or low complement at index); other secondary endpoints included changes in glucocorticosteroid (GCS) use and changes in disease activity. Factors associated with physician-assessed overall clinical response were also evaluated. |
520 ## - SUMMARY, ETC. |
Abstract |
RESULTS: In total, 830 patients were included in the overall population (mean [standard deviation (SD)] age: 41.9 [12.57] years; female: 89.3%; 60.4% from the USA). Nearly half (48.1%) of belimumab-treated patients experienced a >= 50% physician-assessed improvement in their overall manifestations, and 13% achieved a near normalization of their condition (equal to >= 80% improvement). Initiating belimumab while on high-dose (> 7.5 mg/day) GCS use was associated with >= 50% clinical improvement at month 6 (OR: 1.9, p = 0.003). Most (78.1%; n = 518/663) patients were able to reduce or discontinue their oral GCS dose after 6 months of belimumab, with a mean (SD) change of - 8.5 (10.74) mg/day prednisone-equivalent. The mean (SD) change from belimumab initiation in disease activity score (SLEDAI-2K/SELENA-SLEDAI) was - 5.7 (4.5; n = 344). |
546 ## - LANGUAGE NOTE |
Language note |
English |
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
Institution |
MedStar Washington Hospital Center |
656 ## - INDEX TERM--OCCUPATION |
Department |
Medicine/Rheumatology |
657 ## - INDEX TERM--FUNCTION |
Medline publication type |
Journal Article |
700 ## - ADDED ENTRY--PERSONAL NAME |
Local Authors |
Collins, Christopher E |
790 ## - Authors |
All authors |
Collins CE, Cortes-Hernandez J, Gairy K, Garcia MA, Kurtinecz M, Schwarting A, Touma Z, von Kempis J |
856 ## - ELECTRONIC LOCATION AND ACCESS |
DOI |
<a href="https://dx.doi.org/10.1007/s40744-020-00243-2">https://dx.doi.org/10.1007/s40744-020-00243-2</a> |
Public note |
https://dx.doi.org/10.1007/s40744-020-00243-2 |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Koha item type |
Journal Article |
Item type description |
Article |